Liebe HTA-Interessierte,

wir freuen uns, Sie darauf hinweisen zu dürfen, dass folgende neue Berichte (online) veröffentlicht wurden:

HTA-Projektbericht:

• Telemedizinische Diabetesversorgung in Österreich: Eine systematische Analyse von Evaluierungsmethoden. HTA-Projektbericht 143.

Policy Briefs:

• Covid-19: HSS/ Horizon Scanning Living Document (v21 April/ Mai 2022). AIHTA Policy Brief 002.
• Regelung und Finanzierung von pränatalen Screening- und diagnostischen Untersuchungen auf fetale Anomalien in ausgewählten europäischen Ländern. AIHTA Policy Brief 012.

Oncology Factsheets:

• Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 86.
• Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Oncology Fact Sheet Nr. 87.
• Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Oncology Fact Sheet Nr. 88.
• Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Oncology Fact Sheet Nr. 89.
• Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI?H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Oncology Fact Sheet Nr. 90.
• Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Oncology Fact Sheet Nr. 91.
• Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL). Oncology Fact Sheet Nr. 92.
• Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 93.
• Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early?stage triple?negative breast cancer (TNBC). Oncology Fact Sheet Nr. 94.
• Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 95.
• Atezolizumab (Tecentriq®) as adjuvant treatment following complete resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 96.
• Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Oncology Fact Sheet Nr. 97.

Mit freundlichen Grüßen

Ozren Sehic
______________________________________________________________________________

Ozren Sehic, M.A.
Assistenz der Geschäftsführung und Wissenschaftskommunikation
Austrian Institute for Health Technology Assessment
Garnisongasse 7/20, 1090 Vienna
Tel: +43 (0) 1 236 81 19-23
Webseite